Home |  Corporate Info |  R & D |  Products |  Investor Relations |  Careers at Hemispherx  

Rodman & Renshaw 17th Annual Global Investment Conference
Sept. 10, 2015 @ 4:15 PM ET

Presentation only

Presentations from the
Stockholder Open House at Hemispherx's Manufacturing and Research Development Center in New Jersey
August 25, 2015

The Path to Success:  Ampligen

Crossing the finish line -
The final steps:  Alferon

European Commission
dated 24 April 2015:

Adoption of COMMISSION IMPLEMENTING DECISION relating to the designation of "Rintatolimod" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council

Evaluating the efficacy of Ampligen (TLR3 agonist) in mouse model of EBOV infection
updated Feb 2, 2015

BioWorld Today
Chimerix quits Ebola trails as Hemispherx Gets Started
February 3, 2015

11th Biennial Int'l Research and Clinical Conference
San Francisco, CA
March 20-23, 2014

Differential Exercise Responses to Rintatolimod [Ampligen®] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)

(Click here to download poster)

Transcript from Influenza Press Conference at the National Press Club
Washington, D.C.
January 30, 2014
(Click here to download)

Scientific Presentation::

ASM Biodefense Meeting, Washington, D.C.
 January 29, 2014

presented by:  The University of Alabama and Hemispherx BIopharma

Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod (Ampligen®), Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA


Scientific Presentation:

Keystone Symposia Conference on Pathogenesis of Respiratory Viruses
January 21, 2014

Protection from Pulmonary Tissue Damage Associated with Infection of Cynomogus Macaques by Highly Pathogenic Avian Influenza Virus (H5N1):



Research supported by the Center of Excellence for Emerging and Zoonotic Animal Diseases finds potential treatment for drug-resistant H7N9 influenza virus

published by:
Kansas State University
News and Editorial Services
January 16, 2014

Evidence based clinical potential of a natural IFN-αlpha for infection control and treatment

published in:

Expert Review of
Anti-infective Therapy

early online edition pages 1-5, 2014




Company Profile

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders.  Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen®. 

Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection.  Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.

Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.

Ampligen® (poly I:poly C12U) is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching.  Ampligen® and Oragens® experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis and influenza. 

Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases.  Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®).  The Company wholly owns and exclusively operates a GMP certified manufacturing facility in New Brunswick, New Jersey.  

Mail: Hemispherx Biopharma, Inc.


One Penn Center
1617 JFK Blvd., Suite 500
Philadelphia, PA 19103
Phone: (215) 988-0080
Fax: (215) 988-1739
E-mail: info@hemispherx.net

NOTE: We will do our best to respond to all inquires. However, we cannot guarantee individual answers.

Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.